
    
      Aim: To investigate the efficacy of roflumilast in the treatment of psoriasis.

      Design: Multicentre, double-blinded, randomised, placebo-controlled, clinical trial.

      Participants: Patients â‰¥18 years with plaque psoriasis.

      Method: Twelve weeks treatment with either roflumilast or placebo tablets. Both groups
      continue for an additional 12 weeks open-label treatment.

      Primary endpoint: Proportion of patients achieving at least 75% reduction from baseline
      psoriasis area and severity index (PASI75) at week 12.
    
  